姜 廣興

Medicine & Life Sciences

1. Endothelial Progenitor Cells 100%
2. Myocardial Infarction 99%
3. Receptor for Advanced Glycation End Products 65%
4. Albuminuria 58%
5. Toll-Like Receptor 4 57%
6. MK0626 53%
7. Coronary Vessels 43%
8. Chemokine CCL24 43%
9. Heparin Cofactor II 40%
10. Endothelial Cells 39%
11. Chaperonin 60 35%
12. Percutaneous Coronary Intervention 35%
13. Circulating MicroRNA 35%
14. Advanced Glycation End Products 34%
15. Taiwan 33%
16. Dipeptidyl-Peptidase IV Inhibitors 33%
17. Rivaroxaban 32%
18. 3-hydroxy-3-methylglutaryl-coenzyme A 32%
19. Haptoglobins 31%
20. Porphyromonas gingivalis 31%
21. Albumins 30%
22. Angiogenesis Inhibitors 30%
23. Osteoporotic Fractures 29%
24. Vascular Stiffness 29%
25. Essential Hypertension 29%
26. Chronic Obstructive Pulmonary Disease 28%
27. Hydroxymethylglutaryl-CoA Reductase Inhibitors 28%
28. Annexin A5 28%
29. Adiponectin 27%
30. Atherosclerosis 26%
31. Blood Pressure 26%
32. Renin-Angiotensin System 26%
33. Coronary Artery Disease 26%
34. Population 24%
35. Bilirubin 24%
36. Cholesterol 24%
37. Reperfusion Injury 24%
38. Nitric Oxide Synthase 24%
39. Human Influenza 23%
40. Oxidoreductases 22%
41. Atrial Fibrillation 22%
42. Cohort Studies 21%
43. Stents 21%
44. Cardiac Arrhythmias 21%
45. Longitudinal Studies 20%
46. Biomarkers 20%
47. Vaccination 20%
48. Swine 19%
49. Safety 18%
50. Hypertension 17%